Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatment with rio...
Uloženo v:
Hlavní autoři: | Alberto M. Marra, Michael Halank, Nicola Benjamin, Eduardo Bossone, Antonio Cittadini, Christina A. Eichstaedt, Benjamin Egenlauf, Satenik Harutyunova, Christine Fischer, Henning Gall, Hossein Ardeschir Ghofrani, Marius M. Hoeper, Tobias Lange, Karen M. Olsson, Hans Klose, Ekkehard Grünig |
---|---|
Médium: | Artigo |
Jazyk: | angličtina |
Vydáno: |
2018
|
On-line přístup: | https://doi.org/10.1186/s12931-018-0957-y https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-018-0957-y |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
Podobné jednotky
-
Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
Autor: Marra, Alberto M., a další
Vydáno: (2018) -
Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Autor: Alberto M. Marra, a další
Vydáno: (2015) -
Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension
Autor: Christina A. Eichstaedt, a další
Vydáno: (2022) -
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study
Autor: Hossein Ardeschir Ghofrani, a další
Vydáno: (2010) -
Practical management of riociguat in patients with pulmonary arterial hypertension
Autor: Halank, Michael, a další
Vydáno: (2019)